Condition: Ovarian Cancer · Sponsor: ARCAGY/ GINECO GROUP
SALVOVAR will be a pragmatic open-label multicenter randomized phase III trial (ratio 1:1) comparing the efficacy of the salvage weekly dose-dense regimen with those of the continuation of the standard regimen.
This description comes directly from the study's public registry record.
Marine COGNAT · +33 1 84 85 20 20 · salvovar.trial@arcagy.org
Always discuss trial participation with your own doctor first.
| ICO Paul Papin | Angers, France | Recruiting |
| CH d'Avignon | Avignon, France | Recruiting |
| Sainte-Catherine Institut du Cancer Avignon-Provence | Avignon, France | Recruiting |
| Hôpital de la Côte Basque | Bayonne, France | Recruiting |
| CHRU Besançon - Hôpital Jean Minjoz | Besançon, France | Recruiting |
| Institut Bergonié | Bordeaux, France | Recruiting |
| CHU de BREST - Hôpital Cavale Blanche | Brest, France | Recruiting |
| Centre François Baclesse | Caen, France | Recruiting |
| Centre d'Oncologie et de Radiothérapie 37 (ROC37) | Chambray-lès-Tours, France | Recruiting |
| Centre Hospitalier de Cholet | Cholet, France | Recruiting |
| Centre Jean Perrin | Clermont-Ferrand, France | Recruiting |
| Centre Hospitalier Alpes Leman | Contamine-sur-Arve, France | Not Yet Recruiting |
+ 60 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06476184